<DOC>
	<DOCNO>NCT00191438</DOCNO>
	<brief_summary>This phase III randomize study compare two different regimen chemotherapy . The purpose study determine two regimen make tumor small disappear , long . In addition disease-related symptom evaluate . The safety drug determine base upon evaluation side effect</brief_summary>
	<brief_title>Phase III Study Gemcitabine Plus Cytotoxic Agent Versus Two Cytotoxic Agents</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Locally advanced and/or metastatic breast cancer . Measurable disease Previously treat anthracycline Patients inflammatory breast disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>